Literature DB >> 3379136

Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition.

D K Snyder1, D R Clemmons, L E Underwood.   

Abstract

We found in a previous study that injections of GH for 3 weeks caused nitrogen conservation despite restriction of intake to 24 Cal (100 kJ)/kg ideal BW (IBW). To determine the effects of longer periods of treatment and further caloric restriction on nitrogen balance, lipolysis, and body composition, 20 obese (30-67% over IBW) subjects (16 women and 4 men; 20-54 yr old) were fed a diet of 18 Cal (75 kJ)/kg IBW with 1.2 g protein/kg IBW daily for 13 weeks. During weeks 2-12, 10 subjects received injections of recombinant methionyl GH (0.1 mg/kg IBW every other day), and the other 10 sex-, age-, and weight-matched subjects were given injections of saline. There were no significant differences between the two groups in total weight loss [GH, 13.9 +/- 3.0 (+/- SD) kg; saline, 15.2 +/- 3.8 kg ) or the percentage of body fat lost (GH, 8.1 +/- 2.4%; saline, 7.5 +/- 1.5%), although GH injection caused a significant acute increment in serum FFA concentrations (GH, 0.53 +/- 0.37 mmol/L; saline, 0.08 +/- 0.22 mmol/L; P less than 0.001) throughout the study. This acute lipolytic response to GH decreased significantly, from 0.86 +/- 0.32 mmol/L on day 1 of GH treatment to 0.35 +/- 0.41 mmol/L by day 35 of GH injection (P less than 0.01). Nitrogen balance was significantly more positive in the group receiving GH during the first 33 days of the GH injection period [GH, +0.07 +/- 1.82 g/day (+5.0 +/- 130.0 mmol/day); saline, -1.91 +/- 1.10 g/day (-136.3 +/- 78.5 mmol/day); P less than 0.001]. During the last 44 days of GH injection, however, the nitrogen balance in the two groups was similar [GH, -0.90 +/- 1.65 g/day (-64.2 +/- 117.8 mmol/day); saline, -1.08 +/- 0.95 g/day (-77.1 +/- 67.8 mmol/day); P = NS]. Mean plasma insulin-like growth factor I (IGF-I) concentrations rose from a basal value of 1.6 +/- 0.8 to 2.9 +/- 1.2 U/mL by 48 h after the first GH injection and ranged subsequently from 3.2 +/- 1.3 to 4.9 +/- 3.3 U/mL during GH injection (P less than 0.001). In contrast, the mean IGF-I concentration did not change in the group that received saline. Dietary restriction during the first week of study caused serum T3 concentrations to decline in both groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379136     DOI: 10.1210/jcem-67-1-54

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Human growth hormone prevents the protein catabolic side effects of prednisone in humans.

Authors:  F F Horber; M W Haymond
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

3.  Metabolic adaptations to short-term every-other-day feeding in long-living Ames dwarf mice.

Authors:  Holly M Brown-Borg; Sharlene Rakoczy
Journal:  Exp Gerontol       Date:  2013-07-04       Impact factor: 4.032

4.  Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay.

Authors:  Fahri Bayram; Vedia Tonyukuk Gedik; Özgür Demir; Ahmet Kaya; Kürşat Gündoğan; Rıfat Emral; Ahmet Öztürk; Ali Rıza Uysal; Demet Çorapçıoğlu
Journal:  Endocrine       Date:  2011-05-03       Impact factor: 3.633

5.  Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry.

Authors:  Fang Fang Zhang; Esther M John; Julia A Knight; Manleen Kaur; Mary Daly; Saundra Buys; Irene L Andrulis; Beth Stearman; Dee West; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

Review 6.  Obesity, growth hormone and exercise.

Authors:  Gwendolyn A Thomas; William J Kraemer; Brett A Comstock; Courtenay Dunn-Lewis; Carl M Maresh; Jeff S Volek
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

7.  Changes in body composition of children with chronic renal failure during growth hormone treatment.

Authors:  N Vaisman; Z Zadik; R Duchan; H Voet; D Lotan; A Drukker
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 8.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 9.  Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone.

Authors:  N Mauras; M W Haymond
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 10.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.

Authors:  Darlene E Berryman; Camilla A M Glad; Edward O List; Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2013-04-09       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.